Involving A Nucleic Acid Encoding A Receptor, Cytokine, Hormone, Growth Factor, Ion Channel Protein, Or Membrane Transporter Protein Patents (Class 435/6.17)
  • Patent number: 11350886
    Abstract: Infusion devices and related medical devices, patient data management systems, and methods are provided for monitoring a physiological condition of a patient. An exemplary infusion device includes an actuation arrangement operable to deliver fluid to a user, a communications interface to receive measurement data indicative of a physiological condition of the user, a sensing arrangement to obtain contextual measurement data, and a control system coupled to the actuation arrangement, the communications interface and the sensing arrangement to determine a command for autonomously operating the actuation arrangement in a manner that is influenced by the measurement data and the contextual measurement data and autonomously operate the actuation arrangement in accordance with the command to deliver the fluid to the user.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: June 7, 2022
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Huzefa F. Neemuchwala, Pratik Agrawal, Benyamin Grosman, Anirban Roy, Patrick E. Weydt, Louis J. Lintereur, Ali Dianaty, Yuxiang Zhong, Chantal M. McMahon
  • Patent number: 11319380
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 3, 2022
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Rutul R. Shah
  • Patent number: 11253535
    Abstract: A method of treating Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), a cardiomyopathy or a muscular traumatism in a subject includes administering to the subject certain ADP ribosylcyclase antagonist compounds, certain cyclic ADP ribose (cADPR) antagonist compounds, certain nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist compounds or a mixture of these compounds.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 22, 2022
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: José-Manuel Cancela, Sabine De La Porte, Antoine De Zelicourt
  • Patent number: 11221327
    Abstract: Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF, glycodelin and optionally ZAG, in a biological sample from the mammal, and determining that the mammal has endometriosis when the biomarker expression levels in the sample are elevated.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 11, 2022
    Assignees: McMaster University, The Regents of the University of California
    Inventors: Warren Foster, Jocelyn Wessels, Sanjay Agarwal, Leyla Soleymani
  • Patent number: 11141391
    Abstract: Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: October 12, 2021
    Assignee: Rush University Medical Center
    Inventors: Jun Sun, Jingsong Zhou, Shaoping Wu, Jianxun Yi
  • Patent number: 11131677
    Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 28, 2021
    Assignee: University of Washington
    Inventors: Bhagwat Prasad, Abdul Basit, Haeyoung Zhang, John K. Amory
  • Patent number: 10973843
    Abstract: The present invention provides a method of inhibiting tumor-mediated immunosuppression in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of Semaphorin 4D.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: April 13, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventor: Rania H. Younis
  • Patent number: 10961575
    Abstract: A method for sequencing a nucleic acid template includes forming a nanowire assembly including a semiconductor nanowire and a probe covalently bound to the semiconductor nanowire; contacting the nanowire assembly with a template nucleic acid; contacting the nucleic acid duplexes with an extension nucleic acid, the extension nucleic acid joined to the probe; disrupting the nucleic acid duplexes; and measuring an electrical characteristic of a nanowire assembly of the set of nanowire assemblies.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 30, 2021
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Hongye Sun, Steven Fung, Sam Lee Woo
  • Patent number: 10942192
    Abstract: Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 9, 2021
    Inventor: Paul A. Gurbel
  • Patent number: 10927412
    Abstract: The present disclosure provides methods and compositions that are useful for diagnosing the presence or absence of endometriosis and the severity of endometriosis in a subject. The methods and compositions are also useful for distinguishing endometriosis from other uterine or pelvic pathologies in a subject. Also described are sets of genes whose expression levels in a biological sample are diagnostic for endometriosis, and compositions useful for diagnosis, prognosis, and/or treatment of endometriosis.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 23, 2021
    Assignee: The Regents of the University of California
    Inventors: Linda C. Giudice, Juan C. Irwin, John S. Tamaresis
  • Patent number: 10913985
    Abstract: The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Fkbp10, ZdhhC6, Myrip, Actc1, AC124993.19, Runx2, AC158560.4, PlekhB1, Rps6KA2, Sept1, Sprr2k, and Flt1.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 9, 2021
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Uro{hacek over (s)} Jamnikar, Marjanca Blas, Kristina Gruden
  • Patent number: 10907216
    Abstract: The present invention addresses the problem of how to provide a predictive marker useful for carcinogenesis surveillance after hepatitis C virus eradication. Provided is a predictive marker composed of a single nucleotide polymorphism specified by rs17047200. In the present invention, the single nucleotide polymorphism is detected in nucleic acid samples collected from subjects, thereby to examine the risk of developing hepatocellular carcinoma after of hepatitis C virus eradication.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 2, 2021
    Assignee: PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
    Inventors: Yasuhito Tanaka, Kentaro Matsuura
  • Patent number: 10870888
    Abstract: Disclosed herein are methods of detecting, predicting or monitoring a status or outcome of a transplant in a transplant recipient.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: December 22, 2020
    Assignees: The Scripps Research Institute, Northwestern University
    Inventors: Daniel Salomon, Sunil M. Kurian, Steven Head, Michael M. Abecassis, John J. Friedewald, Josh Levitsky
  • Patent number: 10865252
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: December 15, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Patent number: 10787659
    Abstract: The disclosure generally relates to compositions and methods for the extraction of nucleic acids from biological samples. In particular embodiments the extraction involves mixing dibromochloromethane, iodochloromethane or mixtures thereof with a biological sample that has been mixed with a phenol-based extraction solution. Centrifugation of the sample is not needed to achieve phase separation which occurs using the present methods in as little as one to two minutes with no phenol carryover.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: September 29, 2020
    Assignee: LIFE TECHNOLOGIES AS
    Inventors: Darren Ellis, Hannah Lindstroem
  • Patent number: 10501800
    Abstract: The present invention provides gene expression profiles indicative of whether a patient afflicted with PR driven malignancies is likely to be responsive to treatment with a therapeutic compound that is an anti-progestin. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. Also, provided are methods of using gene expression profiles and assays for identifying the presence of a gene expression profile in a patient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 10, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Carol Ann Lange, Todd Philip Knutson, Jason Basil Nikas
  • Patent number: 10370438
    Abstract: Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: August 6, 2019
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Toshiaki Kawakami, Yuko Kawakami
  • Patent number: 10337019
    Abstract: Fungal artificial chromosome (FAC) vectors are disclosed. A vector can be replicated in a bacterial or a fungal host, and can comprise an insert of heterologous DNA up to about 500 kilobases. A vector can be used for cloning and expressing a secondary metabolite (SM) gene cluster. An insert sequence can be modified by homologous recombination. A vector can be a plasmid comprising bacterial and fungal origins of replication, as well as bacterial and fungal selection marker genes. Also disclosed are vectors that can be integrated into a fungal genome, and dual function vectors which can be replicated in a bacterial or a fungal host and can also be integrated into a fungal genome. Also disclosed are methods of generating plasmid libraries including vectors comprising intact SM gene clusters.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: July 2, 2019
    Assignee: INTACT GENOMICS, INC.
    Inventor: Chengcang Charles Wu
  • Patent number: 10287331
    Abstract: Disclosed are fusion protein constructs comprising a functional mitochondrial protein, that can enter mitochondria within intact cells. Further disclosed are methods of treating mitochondrial disorders by the disclosed fusion proteins and compositions therefor.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: May 14, 2019
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Haya Lorberboum-Galski, Hagar Greif
  • Patent number: 10208350
    Abstract: Methods for assessing infertility and related pathologies and informing treatment type and timing thereof are provided. According to certain embodiments, methods of the invention include determining levels of one or more transcripts present in a sample obtained from a subject suspected of having endometriosis, identifying transcript levels that correspond to a regulation pattern specific to a time-point in a uterine cycle, and characterizing endometriosis of the subject based upon the identified transcript levels. The invention includes methods for assessing age-associated increase in aneuploidy rates based on FSH levels and IVF success rates based on obesity in PCOS patients.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Celmatix Inc.
    Inventors: Piraye Yurttas Beim, David Emlyn Parfitt, Michael Elashoff
  • Patent number: 10168314
    Abstract: Described are methods and structures associated with live cell analysis apparatus. A live cell analysis apparatus may include at least one data processor that is configured to process a sequence of images of live cells to determine motion of one or more live cells. The motion may be in response to applied electrical stimulations. The apparatus and methods may be used to determine a refractory period for cardiomyocytes from the determined motion.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: January 1, 2019
    Assignee: SONY CORPORATION
    Inventors: Kazuya Takahashi, Tomohiro Hayakawa, Hirokazu Tatsuta, Eriko Matsui
  • Patent number: 10006087
    Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 26, 2018
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Nancy Bo Yin Tsui
  • Patent number: 9914949
    Abstract: The present invention provides a method for enhancing N-acetylglucosamine production by usage of a recombinant Bacillus subtilis with a glcK knockout. This invention enhanced the production of GlcNAc by knocking out the glcK gene which encodes a glucokinase, thus eliminating the GlcNAc phosphorylation to GlcNAc-6-P. The specific growth rate and content of GlcNAc in the supernatant of the recombinant Bacillus subtilis with the glcK knockout were 0.15 h?1 and 3.0 g/L, respectively, which were 2.32 times and 2.14 times of those of the control strain without glcK knockout. The recombinant Bacillus subtilis of the present invention would be potentially useful for industrial production of GlcNAc.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 13, 2018
    Assignee: Jiangnan University
    Inventors: Long Liu, Jian Chen, Guocheng Du, Jianghua Li, Yanfeng Liu, Hannes Link, Uwe Sauer
  • Patent number: 9863005
    Abstract: Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: January 9, 2018
    Inventor: Paul Walfish
  • Patent number: 9856516
    Abstract: The present disclosure relates to improved methods for the isolation of genomic material and detection of disease related single nucleotide polymorphisms. In some aspects, these methods increase the total recovery of genomic DNA from buccal cell samples by improving cell lysis conditions. In other aspects, these methods allow for the reuse of patient buccal swab samples, reducing the likelihood of having to collect additional patient samples for re-testing. Finally, in some aspects, these methods increase the sensitivity of SNP detection using an improved real-time PCR assay protocol.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: January 2, 2018
    Assignee: AVELLINO LABS USA, INC.
    Inventor: Connie Chao-Shern
  • Patent number: 9562265
    Abstract: Provided herein are primers comprising a nucleotide sequence complementary to a portion of a RhD gene. Also provided herein are methods of determining a RhD zygosity in a subject. Also provided are methods of detecting a weak D allele in a subject. Further provided are kits for determining an RhD zygosity.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: February 7, 2017
    Assignee: Wake Forest University Health Sciences
    Inventor: Jan Rohozinski
  • Patent number: 9250202
    Abstract: A particle detector includes: a conductive nanolayer; insulating nanolayers attached to both sides of the conductive nanolayer; a nanopore formed to penetrate the conductive nanolayer and the insulating nanolayers so as to provide a migration path for a sample particle; a power supply unit configured to apply an electric field between both ends of the nanopore so as to apply a potential to the conductive nanolayer; and an electric signal measuring unit electrically connected to the conductive nanolayer and configured to measure the potential change in the conductive nanolayer induced by the sample particle as the sample particle migrates through the nanopore. The particle detector is capable of detecting a particle with high signal-to-noise ratio and resolution, scanning a sample without mechanical motion of the conductive nanolayer and analyzing DNA base sequences.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: February 2, 2016
    Assignee: SNU R&DB FOUNDATION
    Inventor: Honggu Chun
  • Patent number: 9029080
    Abstract: The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: May 12, 2015
    Assignee: BASF SE
    Inventors: Paul Bernasconi, John Dorsch, Lynn Stam, Scott Zitko, Nancy B. Rankl, Mike Griswold, Franz-Josef Braun, Gang Lu, Robert D. Kirkton, Barbara Wedel, Joachim Dickhaut, Angela Hofhine, Jennifer Zink, Fae Malone, Daniel Houtz, Steffen Groβ, Ramani Kandasamy, Damian O' Brecht London, Thomas M. Gurganus
  • Patent number: 8987266
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Patent number: 8975384
    Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 10, 2015
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • Patent number: 8962589
    Abstract: A variety of methods, devices and compositions are implemented for light-activated molecules. One such method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor (alpha1, Beta2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: February 24, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Raag D. Airan
  • Patent number: 8956818
    Abstract: The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: February 17, 2015
    Assignee: ProteoTech Inc.
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam, Joel Cummings
  • Publication number: 20150044232
    Abstract: The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-CD44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major CD44 isoform in a sample, wherein if the major CD44 isoform is CD44s, the tumor cell or cancer cell is responsive to said anti-CD44 antibody. Also means and methods of treating a cancer patient that has been determined to respond to an anti-CD44 antibody are subject of the present invention.
    Type: Application
    Filed: June 12, 2014
    Publication date: February 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Fabian Birzele, Michael Cannarile, Friedrich Feuerhake, Thomas Fischer, Florian Heil, Konrad Honold, Adam Nopora, Annette Schmitt-Graeff, Edgar Voss, Stefan Weigand
  • Patent number: 8951729
    Abstract: The invention provides to methods for diagnosing eye-length related disorders, including myopia. The invention also provides methods for treating and limiting eye-length related disorders, including myopia. In addition, the invention provides certain haplotypes associated with eye-length related disorders, including myopia and Bornholm Eye Disease.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: February 10, 2015
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Jay Neitz, Maureen Neitz
  • Patent number: 8945865
    Abstract: The present invention provides a method of screening for a compound that enhances or inhibits the transport activity of OATP1B1, using dichlorofluorescein. The present invention also provides a use of dichlorofluorescein in measurement of the expression level of OATP1B1. The present invention further provides a method for measuring the expression level of OATP1B1 in test cells, using dichlorofluorescein. The present invention further provides a use of a kit including dichlorofluorescein and positive cells expressing OATP1B1 in measurement of the expression level of OATP1B1 in test cells.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: February 3, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Saki Izumi, Takafumi Komori, Yoshitane Nozaki
  • Patent number: 8945846
    Abstract: Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jason Robert Gotlib, Garry P. Nolan, James L. Zehnder, Stephen Tracy Oh
  • Patent number: 8940482
    Abstract: A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 27, 2015
    Assignee: Synaptic Research, LLC
    Inventors: George A. Oyler, Yien Che Tsai
  • Patent number: 8916603
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: December 23, 2014
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Stephen B. Liggett, Michael Bristow
  • Patent number: 8883724
    Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: November 11, 2014
    Assignee: Centro de Ingenieria Genética y Biotecnologia
    Inventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
  • Publication number: 20140308209
    Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 16, 2014
    Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
  • Publication number: 20140304846
    Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.
    Type: Application
    Filed: October 29, 2012
    Publication date: October 9, 2014
    Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
  • Patent number: 8846318
    Abstract: The present invention provides a novel method for identifying an olfactory receptor included in one olfactory cell. In the present invention, amplified is the cDNA derived from the mRNA of the one olfactory cell by a PCR method using a forward primer represented by SEQ ID: 01 and a reverse primer represented by SEQ ID: 02. Subsequently, determined is whether or not a gene sequence of the amplified cDNA corresponds with one gene sequence included in gene sequences coding for olfactory receptors included in the mouse olfactory receptor group A. Finally, determined is that the olfactory receptor included in the one olfactory cell is the olfactory receptor which corresponds to the one gene sequence which corresponds with the gene sequence of the cDNA in the previous step, if the gene sequence of the cDNA corresponds with the one gene sequence in the previous step.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: September 30, 2014
    Assignee: Panasonic Corporation
    Inventor: Masato Suzuki
  • Publication number: 20140287425
    Abstract: Described herein are glucose and insulin sensors. The sensors are composed of host cells with DNA specifically designed to produce fluorescence when the cells come into contact with glucose and/or insulin in the sample. Once the fluorescence has been quantified, it can be correlated with the amount of glucose and/or insulin present in the sample.
    Type: Application
    Filed: April 19, 2012
    Publication date: September 25, 2014
    Applicant: INTERNATIONAL PARK OF CREATIVITY
    Inventors: Raul Cuero Rengifo, Juliana Maria Navia
  • Patent number: 8802374
    Abstract: A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 12, 2014
    Assignee: City of Hope
    Inventor: Michael C. Jensen
  • Patent number: 8802377
    Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 12, 2014
    Assignee: Senomyx, Inc.
    Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
  • Publication number: 20140212887
    Abstract: The use of salt-inducible kinase 3 allows screening for a substance having an effect of increasing cartilage volume and/or an effect of normalizing chondrocyte differentiation. A modified chondrocyte in which the expression or function of salt-inducible kinase 3 gene is inhibited or enhanced can be used to ameliorate a disease associated with reduced cartilage volume and/or a disease associated with impaired cartilage growth.
    Type: Application
    Filed: May 29, 2012
    Publication date: July 31, 2014
    Inventors: Noriyuki Tsumaki, Hiroshi Takemori
  • Publication number: 20140206012
    Abstract: Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in tissue engineering as well as identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility. Examples of tissue engineering include techniques that allow for the generation of biological substitutes that restore, maintain, or improve tissue function or a whole organ.
    Type: Application
    Filed: April 1, 2014
    Publication date: July 24, 2014
    Applicant: GenRemedy LLC
    Inventors: Craig S. Atwood, Sivan Vadakkadath Meethal
  • Publication number: 20140187593
    Abstract: Methods and compositions relating to diagnosing and treating a VMAT-2 deficiency disease are described. Provided are methods for screening for, diagnosing or detecting a risk of developing a VMAT-2 deficiency disease comprising detecting the presence of a VMAT-2 variant in a sample of a subject, wherein the presence of the VMAT-2 variant is indicative that the subject has a VMAT-2 deficiency disease or an increased risk of developing a VMAT-2 deficiency disease compared to an individual having wild type VMAT-2. Also provided are methods of treating a VMAT-2 deficiency disease with a dopamine agonist.
    Type: Application
    Filed: December 4, 2013
    Publication date: July 3, 2014
    Inventor: Berge Minassian
  • Publication number: 20140178892
    Abstract: The invention relates to a method of screening for a compound useful in the treatment of a disease selected from neurodegenerative diseases and neuro-inflammatory diseases, said method comprising providing a test cell; staining at least one organelle of said test cell; contacting said test cell with a test compound; and recording the path of said stained organelle in said test cell. Suitable compounds are identified from a comparison of the recorded path with a suitable reference.
    Type: Application
    Filed: April 24, 2012
    Publication date: June 26, 2014
    Inventors: Robert Zorec, Matjaz Stenovec, Sasa Trkov, Nina Vardjan, Maja Potokar, Marko Kreft, Mateja Gabrijel, Jernej Jorgacevski
  • Patent number: 8758994
    Abstract: Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: June 24, 2014
    Assignee: Exelixis, Inc.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Lynn Margaret Bjerke